Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q3

9273.TEDINET S100TEGN
Period2023-07-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥16.8bn2023-07-01 → 2024-03-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥16.2bn2022-07-01 → 2023-03-31Cons.Net sales
Operating income¥3.6bn2023-07-01 → 2024-03-31Cons.Operating income
Operating income¥3.3bn2022-07-01 → 2023-03-31Cons.Operating income
Ordinary income¥3.6bn2023-07-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.2bn2022-07-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥3.6bn2023-07-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥3.2bn2022-07-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss
Net income¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss
Total assets¥30.0bnat 2024-03-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.5bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥7.3bnat 2024-03-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.7bnat 2024-03-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥20.3bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥10.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
EPS (basic)¥57.12023-07-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.642024-01-01 → 2024-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥52.482022-07-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.292023-01-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio75.7%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio73.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-03-31−¥11m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥10.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥2.1bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥1.5bn
—segment totalrevenue2023-07-01 → 2024-03-31¥18.0bn
—segment totalrevenue external2023-07-01 → 2024-03-31¥16.8bn
—segment totalrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
—segment totalsegment profit2023-07-01 → 2024-03-31¥3.6bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-03-31¥16m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥10.2bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥2.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥1.2bn
—segment totalrevenue2022-07-01 → 2023-03-31¥17.5bn
—segment totalrevenue external2022-07-01 → 2023-03-31¥16.2bn
—segment totalrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
—segment totalsegment profit2022-07-01 → 2023-03-31¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 356
ItemContextValueUnit
Ordinary incomePrior1YTDDuration3213891000JPY
Ordinary incomeCurrentYTDDuration3572071000JPY
Income before income taxesPrior1YTDDuration3213891000JPY
Income before income taxesCurrentYTDDuration3572071000JPY
Income taxes currentPrior1YTDDuration1125972000JPY
Income taxes currentCurrentYTDDuration1294951000JPY
Income taxes deferredPrior1YTDDuration8759000JPY
Income taxes deferredCurrentYTDDuration14825000JPY
Income taxesPrior1YTDDuration1134732000JPY
Income taxesCurrentYTDDuration1309776000JPY
Profit lossPrior1YTDDuration2079159000JPY
Profit lossCurrentYTDDuration2262294000JPY
Profit loss attributable to owners of parentPrior1YTDDuration2079159000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2262294000JPY
Profit lossPrior1YTDDuration2079159000JPY
Profit lossCurrentYTDDuration2262294000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-3951000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration24820000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration-12873000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-12785000JPY
Other comprehensive incomePrior1YTDDuration-16824000JPY
Other comprehensive incomeCurrentYTDDuration12035000JPY
Comprehensive incomePrior1YTDDuration2062335000JPY
Comprehensive incomeCurrentYTDDuration2274330000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration2062335000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration2274330000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember10175731000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember5983273000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember16159005000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration16159005000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember1369885000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember1369885000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-1369885000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember11545616000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember5983273000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember17528890000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-1369885000JPY
Net salesPrior1YTDDuration16159005000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember2026088000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember1234068000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember3260157000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember15970000JPY
Operating incomePrior1YTDDuration3276128000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember10273422000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember6499056000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember16772478000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-07-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-07-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass